The Event. Q2 numbers landed this morning. Headline net loss of $32.7 million, or $(1.26)/share — up from $23.5M a year ago. On paper that looks like a company burning harder. It isn’t.
The Reality. $13.9 million of that quarterly loss is a non-cash mark-to-market charge on warrant liabilities, and $21.0 million across the first half. The warrants got more expensive to carry because the stock went up. Operating loss actually improved to $19.2 million from $21.9 million. Cash used in operations for the half was $25.4 million versus $39.3 million in 1H25.
The Thing That Matters. Buried in Note 3: on June 10, 2026, Precision and Banc of California amended the term loan and pushed the maturity from June 30, 2027 to December 31, 2029. In my deep dive I called out “a $22.5M term loan maturing June 30, 2027” as one of the specific ways this capital structure could force a bad raise at a bad moment. That particular gun is no longer pointed at 2027.
The Receipts
The maturity extension. The $22.5M 2024 Term Loan now matures December 31, 2029 instead of June 30, 2027, at a 5.25% stated rate. The $26.3M restricted cash collateral requirement stays — Precision must keep unencumbered cash in the Banc of California security account at least equal to the outstanding principal. Why it matters: the spendable-versus-headline cash gap I flagged is unchanged ($86.1M cash and equivalents plus $26.3M restricted = the $112.4M they advertise), but the refinancing cliff that would have landed right on top of the NUC-withdrawal readout window has been pushed two and a half years out. That’s the single most useful thing in this filing.
The ATM stayed sheathed. Net cash from financing activities for the six months: $0.7 million — and that’s employee stock purchase plan and licensee share purchases. Zero ATM issuance in 1H 2026, versus $14.8 million drawn in 1H 2025. Why it matters: I wrote that “the 2028 runway is not funded by cash on hand alone; it is funded by selling stock.” Management has now gone two full quarters without touching it, including a quarter where the stock traded above $8. That’s discipline, not capacity — the ATM language is still verbatim in the liquidity section — but a company that sells into every uptick would have sold into this one.
The C-suite shuffle (effective August 1, 2026). Alex Kelly moved from CFO to a newly created COO role; Naresh Tanna, previously VP of Investor Relations and Chief of Staff to the CEO, was promoted to CFO. Cassie Gorsuch, PhD, now runs all research functions including clinical-stage translational sciences. The Tea Leaf Reading: this is an internal promotion chain, not an outside hire and not a departure — Kelly stayed, he just moved sideways-and-up into “customer-facing functions.” In small-cap biotech, “customer-facing” is usually shorthand for business development and partnering. Creating a COO seat and pointing it at partnerships nine months before a year-end data drop is a tell worth noting, though it’s a tell, not a transaction.
Burn is real but contained. R&D of $12.4M for the quarter ($2.0M direct PBGENE-HBV, $4.3M direct PBGENE-DMD), G&A down to $6.8M from $9.1M on “operational discipline and lower employee-related costs.” Headcount is 67 full-time employees. Accumulated deficit: $579.3 million. Why it matters: run-rate operating burn is roughly $19M/quarter against $86.1M spendable cash. The 1H revenue of $10.8M — the $6.8M TG milestone plus $4.0M from the legacy agriculture license that concluded in April — does not repeat. Q2 revenue was $0, exactly as I said it would be.
Both programs reaffirmed for year-end 2026. ELIMINATE-B has opened new sites and is expanding Cohort 4 (0.4 mg/kg) and Cohort 5 (0.65 mg/kg) with additional biopsies. FUNCTION-DMD has two active sites — Arkansas Children’s and Washington University — and is actively recruiting, with initial safety data targeted year-end. No timeline slippage disclosed.
